News for Alnylam Pharmaceuticals, Inc. (A1LN34.SA)

Alnylam Pharmaceuticals (ALNY) has received a significant endorsement from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in c

Bank of America has increased its price target for Alnylam Pharmaceuticals (ALNY), revising it upward to $328 from the previous $325. The financial institution

Summary Alnylam Pharmaceuticals Inc (ALNY), a pioneer in RNA interference (RNAi) therapeutics, has announced that it will release its financial results for the

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

In a recent update, Morgan Stanley revised its price target for Alnylam Pharmaceuticals (ALNY), reducing it from $284 to $268 while maintaining an "Equal Weight

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, immigration, and global geopolitics, resulting in elevated levels of uncertainty and...

Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), UnitedHealth Group Incorporated (UNH) and Toyota Motor Corporation (TM), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH).

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an analysis of ALNY stock now.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrati

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overvi

Alnylam Pharmaceuticals Inc (ALNY), a leader in RNAi therapeutics, announced the retirement of Dr. Phillip A. Sharp from its Board of Directors, effective May 8

[url="]Alnylam Pharmaceuticals, Inc.[/url] (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D.

Strengths: Innovative AOC platform and robust pipeline with potential for significant market impact.Weaknesses: Lack of commercialization experience and high R

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

Start Time: 08:30 January 1, 0000 9:28 AM ETAlnylam Pharmaceuticals, Inc.